Open Access

Combined methylmalonic acidemia and homocysteinemia presenting predominantly with late-onset diffuse lung disease: a case series of four patients

  • Jinrong Liu1,
  • Yun Peng2,
  • Nan Zhou3,
  • Xiaorong Liu3,
  • Qun Meng3,
  • Hui Xu1 and
  • Shunying Zhao1Email author
Orphanet Journal of Rare Diseases201712:58

https://doi.org/10.1186/s13023-017-0610-8

Received: 15 June 2016

Accepted: 8 March 2017

Published: 21 March 2017

Abstract

Combined methylmalonic acidemia (MMA) and homocysteinemia are a group of autosomal recessive disorders caused by inborn errors of cobalamin metabolism, including CblC, D, F, and J, with cblC being the most common subtype. The clinical manifestations of combined MMA and homocysteinemia vary, but typically include neurologic, developmental and hematologic abnormalities.

We report 4 children with combined MMA and homocysteinemia who presented predominantly with late-onset diffuse lung diseases (DLD). Of these, 3 accompanied by pulmonary arterial hypertension (PAH), 1 accompanied by hypertension, and 2 accompanied by renal thrombotic microangiopathy (TMA), which was confirmed by renal biopsy. This confirms combined MMA and homocysteinemia should be considered in the differential diagnosis of DLD with or without PAH or renal TMA.

Keywords

Methylmalonic acidemia Homocysteinemia Homocystinuria Diffuse Lung disease Hypertension arterial pulmonary Children

Letter to the editor

In adults, it is reported that isolated hyperhomocysteinemia may damage blood vessels, causing pulmonary arterial hypertension (PAH) and/or pulmonary thromboembolism [1, 2]. Both microangiopathy and thromboembolism can be the underlying mechanisms for pulmonary hypertension in CblC deficiency [38], but an association between MMA and/or homocysteinemia and diffuse lung disease (DLD) has not been broadly reported.

Here, we report a series of 4 pediatric patients with combined MMA and homocysteinemia who developed late-onset DLD. Of these, 3 presented with concomitant PAH, 1 presented with concomitant hypertension, and 2 presented with concomitant renal thrombotic microangiopathy (TMA), which was confirmed by renal biopsy. The main novelty of these cases was the predominantly pulmonary symptomatology at presentation (i.e., chronic wet cough or respiratory failure), with or without PAH (as in the first episode of “pneumonia” or “asthma” of patient 1, 3 and 4), the HRCT imaging findings, and the lack of typical neurological sequelae and ophthalmological findings. We speculate that pulmonary microangiopathy secondary to combined MMA and homocysteinemia was the primary cause of DLD in all 4 cases. Therefore, combined MMA and homocysteinemia should be considered in the differential diagnosis of DLD with or without PAH or renal TMA. This diagnosis should be investigated promptly with the proper metabolic investigations (total plasma homocysteine, plasma acylcarnitine and urine organic acid profiles), so that treatment can be initiated in a timely fashion, as lung disease secondary to this metabolic disorder will respond to appropriate treatment but may not respond to symptomatic treatment.

Case reports

Patient 1

A 21-month-old girl was transferred to our department with a 6-month history of slight productive cough and a 2-month history of shortness of breath. She had previously been treated with intermittent antibiotics but the cough was not resolved. Two months before admission, she had developed shortness of breath and fever, and been diagnosed with pneumonia. Echocardiography showed mild tricuspid and pulmonary valve regurgitation with a tricuspid regurgitation pressure gradient (TRPG, an estimate of pulmonary artery pressure) of 26 mmHg, which suggested that pulmonary artery (PA) pressure was normal. High-resolution computed tomography (HRCT) showed diffuse interstitial pneumonia, consolidation and pleural effusions. Fever, pulmonary consolidation and pleural effusions were resolved after treatment with antibiotics and glucocorticoids at her local hospital, but her shortness of breath and productive cough got worse.

On admission to our hospital, the patient was dyspneic, with nasal alar flaring and retraction, cyanosis in the lips and nail beds. There were no rales or cardiac murmurs on auscultation of the chest. The laboratory investigations showed a white blood cell count of 14,090/mL with 66.6% neutrophils, hemoglobin (Hb) 9.8 ~ 12.6 g/dL, platelet 322 ~ 387 × 109/L, serum lactate dehydrogenase (LDH) 563 IU/L and indirect bilirubin (IBIL) 33.5 μmol/L; and normal serum C-reactive protein concentration and renal function. The urinalysis showed protein in urine ranging from negative to 2+ and red blood cells (RBCs) from 0 ~ 2/HP to 2 ~ 6/HP. Arterial blood gas analysis showed type 1 respiratory failure and a mild metabolic acidosis. Sputum cultures were negative for bacterial, fungal and mycobacterial infection. An HRCT scan of her chest showed diffuse ground-glass opacification in the lower regions of the lungs, areas of smooth thickening of the interlobular septum and increased PA diameter (Fig. 1a). Echocardiography showed moderate PAH (TRPG 68 mmHg) with moderate dilation of the right atrium and ventricle, mild tricuspid and pulmonary valve regurgitation, and an ejection fraction (EF) of 74%. Based on the bilateral diffuse lung lesion of unknown reasons, mild metabolic acidosis, and her low BMI, we suspected she suffered from metabolic disease. Laboratory testing showed elevated concentration of methylmalonic acid in the serum (0.218 mg/dL) and urine (0.428 mg/dL, >420 times the reference value), and a high plasma homocysteine (Hcy) concentration (>50.0 μmol/L, reference range 5~15 μmol/L). Magnetic resonance imaging (MRI) of the brain was performed, which revealed dilated lateral ventricles with mild hydrocephalus, although she had no sigh of neurologic abnormalities. Genetic analysis confirmed a compound heterozygosity in MMACHC, with c.80A > G(p.Q27R) and c.331C > T(p.R111Ter) sequence variants, inherited from the patient’s mother and father, respectively. Combined MMA with homocysteinemia, CblC type/CblC defect/CblC deficiency was confirmed.
Fig. 1

Lung CT showing the presence in both lungs of 1a diffuse ground-glass opacification predominant in lower region of lung and areas with smooth thickening of interlobular septum (on admission; Patient 1), 1b absence of abnormal pulmonary feature(after 1 month of treatment; Patient 1), 2a interlobular septal thickening and bilateral pleural effusion (1 year before admission; Patient 2), 2b diffuse poorly defined centrilobular nodules(5 days after treatment; Patient 2), 2c pulmonary artery (PA) with an enlarged diameter exceeding the aorta(5 days after treatment; Patient 2), and 3 diffuse poorly defined ground-glass centrilobular nodules(on admission; Patient 3)

At diagnosis on day 7 of her admission to our hospital, treatment with captopril (3.125 mg twice daily orally) and vitamin B12 (cyanocobalamin, 0.5 mg daily intramuscularly) was started. She had improved significantly by day 10. On day 13, we added folate (5 mg once daily orally), betaine (250 mg/kg once daily orally), levocarnitine (100 mg/kg once daily orally) and vitamin B6 (10 mg/kg twice daily orally) to her therapeutic regime. Her symptoms improved gradually. One month later, HRCT of the lung showed significant improvement (Fig. 1b), but she continued to require intermittent low-flow supplemental oxygen for a further 4 months. At follow-up 1 year later, echocardiography found normal PA pressures and lung CT findings were normal. She was asymptomatic at 3 years’ follow-up.

Patient 2

A girl aged 4 years and 7 months presented with a 1-year history of slight cough and shortness of breath. She had been observed to have lower than expected levels of physical activity, and slightly delayed intellectual and language development since birth. Echocardiography and MRI of the brain undertaken when she was 1 year old had been normal. She had been admitted to her local hospital 1 year previously due to bilateral palpebral edema, and slight cough and shortness of breath. Echocardiography undertaken at the time showed PAH, blood routine test showed a hemoglobin level of 7.7 g/dL and a platelet count of 161 × 109/L, urinalysis showed proteinuria (2+) and microscopic hematuria, and HRCT showed interlobular septal thickening and bilateral pleural effusions (Fig. 1c). After treatment with bosentan, a diuretic and captopril, the palpebral edema, proteinuria and pleural effusions resolved gradually, but her cough, dyspnea and PAH did not improve, and HRCT revealed multiple nodular lesions in both lungs, so she was referred to our department.

On admission to our hospital, physical examination revealed she had cyanosis of the lips and nail beds. Chest auscultation revealed a second-degree systolic heart murmur but no rales in the lungs. Laboratory investigations detected increased serum LDH (384 IU/L) and blood urea nitrogen (BUN) concentration (11.64 mmol/L, normal range 1.7~ 7.1 mmol/L). Urinalysis revealed protein in urine 2+ and RBCs ranging from 0 ~ 2/HP to 4 ~ 6/HP. We undertook metabolic studies for her slight development delay and renal injury. Methylmalonic acid concentrations were elevated in the serum (0.294 mg/dL) and urine (0.354 mg/dL, >350 times the reference value), and a plasma Hcy concentration was >50.0 μmol/L. Therefore ophthalmologic examination was performed, which revealed bilateral macular coloboma. Echocardiography showed severe PAH (TRPG 81 mmHg) with moderate dilation of the right atrium and ventricle, EF 68%, moderate tricuspid regurgitation and mild pulmonary regurgitation. Her parents did not consent to her undergoing genetic testing. Combined MMA with homocysteinemia was clinically diagnosed.

After diagnosis on day 5 of her admission to our hospital, she was started on treatment with parenteral cyanocobalamin, levocarnitine, vitamin B6 and betaine. Her symptoms improved gradually. On day 10, contrast-enhanced lung CT showed diffuse poorly defined centrilobular nodules, and dilation of the PA to a diameter exceeding that of the aorta (Fig. 1d, e). By day 13, she was more active and was able to get out of bed. On day 15, oxygen treatment was discontinued. On day 22, echocardiography showed mild to moderate PAH (TRPG 60 mmHg) with mild dilatation of the right atrium and ventricle, mild tricuspid regurgitation and mild pulmonary regurgitation. At follow-up 2 months later at her local hospital, lung CT and echocardiography showed further substantial improvements. Unfortunately, she died suddenly 6 months later without an autopsy.

Patient 3

A girl aged 8 years and 5 months was admitted to our hospital for investigation after a 6-year history of decreased activity and intermittent vomiting and diarrhea, and a 2-year history of renal impairment and slight productive cough. Two years before admission, she had been diagnosed with renal failure, hypertension and moderate anemia. Based on her clinical characteristics, she was suspected of having Goodpasture syndrome or vasculitis at her local hospital. At that time, urinalysis showed proteinuria 2+ and microscopic hematuria, and the lung CT revealed diffuse interstitial and parenchymal infiltration.

On admission to our hospital, physical examination revealed she had mild cyanosis of the nail beds. There were no rales or heart murmurs on auscultation of the chest. In laboratory investigations she had elevated BUN (7.73 mmol/L), serum creatinine (115 μmol/L) and IBIL (21.9 μmol/L) concentrations. Routine blood tests showed low hemoglobin (9.6 ~ 11.5 g/dL) without thrombocytopenia. The urinalysis revealed protein in urine ranging from negative to 2+ and RBCs from 0 ~ 2/HP to 2 ~ 4/HP. Diffuse poorly defined ground-glass centrilobular nodules were seen on HRCT (Fig. 1f). Echocardiography was normal, with no evidence of PAH. We undertook metabolic studies for her renal failure of unknown reasons. Methylmalonic acid concentration in the serum was 0.299 mg/dL and in the urine was 0.127 mg/dL (>120 times the reference value); plasma Hcy concentration was >50.0 μmol/L. Therefore brain MRI was performed, which revealed evident demyelinating lesions, although she had no sign of neurologic abnormalities. Genetic analyses confirmed a compound heterozygosity in MMACHC, with c.80A > G(p.Q27R) and c.609G > A(p.W203X) sequence variants, inherited from the patient’s mother and father, respectively. Mutation screening of atypical hemolytic uremic syndrome (HUS) associated genes (CFHR1, CFHR3, CFH, CD46, CFI, CFB, C3 and THBD), PAH associated genes (SMAD9, CAV1, KCNK3, CTEPH1, CPS1 and SARS2), pulmonary venous occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH) associated genes (BMPR2, EIF2AK4) showed no abnormalities. Combined MMA with homocysteinemia, CblC type was confirmed.

On day 1 after admission, she was treated with oral amlodipine besylate and fosinopril. On day 6, after diagnosis, treatment with parenteral cyanocobalamin, folate, levocarnitine, vitamin B6 and betaine was initiated. Renal biopsy undertaken on day 7 subsequently revealed mesangioproliferative glomerulonephritis and TMA with stenotic and occlusive capillaries and ischemic sclerosis. By day 10, her physical strength was improving. On day 11, bronchoscopy was performed and there was no evidence of hemosiderin-laden alveolar macrophages in the bronchoalveolar lavage fluid (BALF). She improved significantly at 9 months’ follow-up.

Patient 4

A boy aged 7 years and 8 months was referred to our respiratory department because of a month period of mild wet cough particularly in the morning and shortness of breath. The HRCT showed mild diffuse ground-glass opacification in both lungs. Echocardiography revealed severe PAH. Asthma was suspected. After receiving a treatment with montelukast and repeated antibiotics for 1 month, and sildenafil and captopril for 15 days, his shortness of breath and PAH (mild to moderate) dramatically improved, but the cough was not resolved. When he was 4 months of age, he had hemolytic anemia without thrombocytopenia or kidney damage. Additionally, he had been diagnosed with acute glomerulonephritis with mild microscopic hematuria 1 year earlier.

On admission to our department, physical examination revealed no rales or heart murmurs on auscultation of the chest. We highly suspected he had combined MMA with homocysteinemia. Laboratory investigations showed a hemoglobin of 10.4 g/dL and mildly elevated LDH (330 IU/L), BUN (9.67 mmol/L), and Cr (71 μmol/L). Urinalysis only revealed sparse RBCs. Blood smear examination revealed sparse fragmented and deformed RBC. The serum and urinary methylmalonic acid concentrations were 0.383 mg/dL and 0.1034 mg/dL (>103 times the reference value) respectively, and plasma Hcy concentration was 193.76 μmol/L. Brain MRI revealed evident demyelinating lesions, although he had no sign of neurologic abnormalities. Genetic analyses confirmed a compound heterozygosity in MMACHC, with c.80A > G(p.Q27R) and c.609G > A(p.W203X) sequence variants, inherited from the patient’s father and mother, respectively. Mutation screening of atypical HUS and PAH associated genes showed no abnormalities. Combined MMA with homocysteinemia, CblC type was confirmed.

After admission, he was continuously treated with oral sildenafil and captopril. On day 4, treatment with parenteral cyanocobalamin, folate, levocarnitine, vitamin B6 and betaine was initiated. Renal biopsy undertaken on day 6 subsequently revealed TMA with stenotic capillaries, ischemic sclerosis, and membranoproliferative glomerulonephritis. Transbronchoscopic lung biopsy undertaken on day 9 subsequently revealed a thickening of the alveolar septum with a small quantity lymphatic tissue and lymphocytes. There was no evidence of hemosiderin-laden alveolar macrophages in the BALF. On day 15, his cough improved significantly and echocardiography just showed mild PAH.

In all 4 patients, metabolic investigations were suggestive of cobalamin deficiency, with elevated blood propionylcarnitine (C3) concentration as well as an elevated propionylcarnitine–acetylcarnitine (C3/C2) ratio, in the context of low or normal concentrations of methionine. Clinical characteristics and results of auxiliary examination of the 4 patients are summarized in Tables 1, 2 and 3.
Table 1

Demographic and clinical features, genetic evaluation and prognosis of 4 Chinese patients with combined MMA and homocysteinemia

 

Patient 1

Patient 2

Patient 3

Patient 4

Gender

Female

Female

Female

Male

Age

21 months

4-years-7-months

8-years-5-months

7-years-8-months

Presentation

Cough,dyspnea

Slightly delayed intellectual and language development, cough,

short of breath

Decreased activity, vomiting,diarrhea, abnormal renal function,cough

Mild wet cough and shortness of breath

Weight(kg)/PCSAG

9.0/<3rd percentile

14.0/3rd percentile

18.5/<3rd percentile

16.0/<3rd percentile

Height(cm)/PCSAG

83/30th percentile

112/90th percentile

118/<3rd percentile

123/23th percentile

Head circumference(cm)

45.1/(normal)

No record

No record

50.2/(normal)

BMI(kg/m2)/PCSAG

13.0/<3rd percentile

11.16/<3rd percentile

13.29/8th percentile

10.58 < 3rd percentile

Respiratory rate(breaths/min)

40

28

22

20

Heart rate(beats/min)

145

102

110

90

Blood pressure(mmHg)

90/55

90/60

130/100

95/60

Clubbed fingers

+

+

+

+

Fundus examination

Normal

Bilateral macular coloboma

Normal

Normal

MMACHC gene

c.80A > G(p.Q27R),

c.331C > T(p.R111Ter)

Not available

c.80A > G(p.Q27R),

c.609G > A(p.W203X)

c.80A > G(p.Q27R),

c.609G > A(p.W203X)

Genotype

CblC

Not available

CblC

CblC

Follow-up

3 years

6 months

9 months

1 month

Prognosis

Asymptomatic

Improvement, but died suddenly

Improvement

Improvement

Abbreviations: BMI body mass index; CblC cobalamin C; PCSAG percentile of the children with same age and gender

Table 2

Laboratory features of 4 Chinese patients with combined MMA and homocysteinemia

 

Patient 1

Patient 2

Patient 3

Patient 4

Hemoglobin(g/dL)

9.8 ~ 11.6

11.5 ~ 12.5

9.6 ~ 11.5

104

MCV(fL)

113.4 ~ 118.6

91.3 ~ 92.5

89.4 ~ 94.6

103.8

Platelet(×109/L)

322 ~ 387

161 ~ 317

249 ~ 332

502

Urine protein

Negative ~ 2+

2+

Negative ~ 2+

Negative

Urinary erythrocytes

0-2/HP ~ 2-6/HP

0-2/HP ~ 4-6/HP

0-2/HP ~ 2-4/HP

sparse

Arterial blood gas analysis

PaO2: 27 mmHg, mild metabolic acidosis

PaO2: 49 mmHg

PaO2: 60 mmHg

PaO2: 83 mmHg

Liver function,serum albumin, cholesterol, triglyceride

Normal

Normal

Normal

Normal

IBIL (μmol/L)

33.5

10.5

21.9

8.69

BUN(mmol/L)

7.1

12.37

BUN7.73

BUN9.67

Cr (μmol/L)

38

67

115

71

eGFR (80–120 mL/min/1.73 m2)

81

61

37

64

Serum LDH(IU/L)

563(normal range:50 ~ 240)

384(normal range:50 ~ 240)

286(normal range:110 ~ 295)

330((normal range: 110 ~ 295)

Methionine concentrations (normal range:8.6 ~ 23.3 μmol/L)

7.6

22.6

8.4

11.1

Serous vitamin B12

Normal

Normal

Normal

Normal

Serous folate

Normal

Normal

Normal

Normal

Complement C3,C4

Normal

Normal

Normal

Normal

Thyroid hormones

Normal

Normal

Normal

Normal

Immune globulin

Normal

Normal

Normal

Normal

Lymphocyte subsets

Normal

Normal

Normal

Normal

Serum ceruloplasmin

Normal

Normal

Normal

Normal

ANA,dsDNA,ACA, ANCA

Negative

Negative

Negative

Negative

Anti-GBM Ab

Negative

Negative

Negative

Negative

Coombs test

Negative

Negative

Negative

±

Bone marrow examination

Megaloblastic anemia

Normal

Megaloblastic anemia

Normal

Abbreviations: ANA antinuclear antibody; ACA anticardiolipin antibody; ANCA antineutrophil cytoplasmic antibody; anti-GBM Ab-Anti-glomerular basement membrane antibody; BUN blood urea nitrogen; Cr creatinine; dsDNA double stranded DNA antibody; eGFR estimated glomerular filtration rate; LDH lactate dehydrogenase; IBIL indirect bilirubin concentration; MCV Mean Corpuscular Volume

Table 3

Imaging features of 4 Chinese patients with combined MMA and homocysteinemia

 

Patient 1

Patient 2

Patient 3

Patient 4

PAH

+

+

+

EF(%)

74

68

75

77

Abdominal ultrasonography

Echo enhancement of the renal parenchyma on both sides

Mild enlargement of both kidneys

Echo enhancement and diffuse injury to the renal parenchyma on both sides

Normal

Brain MRI

Dilated lateral ventricles with mild hydrocephalus

Normal

Demyelinating lesions

Demyelinating lesions

Lung CT

Diffuse ground-glass opacification, interlobular septal thickening

Diffuse poorly defined centrilobular nodules, interlobular septal thickening

Diffuse poorly defined ground-glass centrilobular nodules

Mild diffuse ground-glass opacification,

Abbreviations: EF ejection fraction; MRI magnetic resonance imaging; PAH pulmonary arterial hypertension

Discussion

In this case series of children with combined MMA and homocysteinemia presenting predominantly with late-onset DLD, 3 cases also had PAH and 1 had hypertension. The diagnosis was made in each of the patients mainly on the basis of clinical features of multisystem damage, elevated serum and urine methylmalonic acid concentrations, elevated plasma homocysteine concentration, and elevated blood C3 concentration and C3/C2 ratio. Combined MMA with homocysteinemia results from deficient synthesis of the coenzymes derived from vitamin B12. So far, eight variants have been described, cobalamin C (CblC) being the most prevalent. The Cb1C defect was confirmed in patients 1 (c.80A > G, c.331C > T), 3(c.80A > G, c.609G > A) and 4 (c.80A > G, c.609G > A). Patient 2 had macular coloboma, which is supportive of a cblC defect, however her parents refused to give consent for the genotyping analysis. All 3 patients carried the c.80A > G mutation which has been reported in 4 Chinese patients with TMA or PAH [9]. The c.331C > T mutation was associated with the early-onset form mainly in the French, Canadian, Acadian and Cajun populations [10, 11], and has been reported in 1 Chinese patient [12]. The c.609G > A mutation is a hot spot mutation in Chinese patients with CblC defect [12, 13] and has been reported in 2 Chinese patients with HUS [14]. Patient 3 and 4 carried compound heterozygous mutations (c.80A > G, c.609G > A), which have been reported in eight Chinese patients with early-onset of the condition [12, 13], and 1 late-onset Chinese patient with PAH and renal TMA [9]. However, to date, the most frequent MMACHC mutations associated with PAH and renal TMA were c.271dupA, c.276G > T, and c.565C > A in Western countries [47, 15, 16].

Combined MMA and homocysteinemia is a multisystemic disorder that can lead to damage to the central nervous system, retina, liver, kidneys and bone marrow (http://www.ncbi.nlm.nih.gov/books/NBK1328/). In our series, all patients had evidence of renal injury, hematologic and neurologic abnormalities to some extent;patient 2 also had bilateral macular coloboma, which are also common in combined MMA and homocysteinemia. Cardiomyopathy, both dilated, hypertrophic and non compaction, as well as microangiopathy have been described in patients affected with this group of conditions [17]. There have been 2 reports of pulmonary embolism and PAH in children with cobalamin C defect [3, 18], 7 of PAH in patients(including 1 adult) with cobalamin C defect [47, 9, 15, 16], 1 of PAH in newborn with MMA [19]. PVOD has been described as histological diagnosis in 3 patients with CblC defect [6, 16]. Contrast-enhanced lung CT was performed in patient 2 and didn’t show thin pulmonary venous or pulmonary artery embolism. DLD improved significantly after treatment in all patients, which didn’t suggest PVOD. In addition the lung abnormalities identified on imaging were not sufficiently severe to have caused PAH. Therefore we consider PAH was caused by combined MMA and homocysteinemia.

In this study, we aimed to show that there may be a relationship between combined MMA and homocysteinemia and DLD in children, although interstitial lung disease has been reported in association with other syndromes such as Niemann-Pick disease, as well as pulmonary alveolar proteinosis. No other causes of DLD, such as connective tissue disease, alveolar hemorrhage syndromes, pulmonary vasculitis, hypersensitivity pneumonitis, drug induced interstitial pneumonia, or infection were detected in any of the patients. Thus we think that in these cases, it is highly possible that DLD was caused by combined MMA and homocysteinemia, and not by PAH, based on the following reasons. Respiratory symptoms arose before or at the time of PAH diagnosis in the first 2 patients and in patient 4. Additionally, DLD existed in the absence of PAH in patient 3, despite lung imaging being similar to that in patient 2. Furthermore, DLD improved substantially in all patients when they were treated for MMA and homocysteinemia, but patient 2 did not improve when she was treated with bosentan.

Post mortem examination of 4 patients with combined MMA and homocysteinemia found severe vascular lesions, with renal damage characteristic of TMA [20, 21], thromboemboli in the pulmonary circulation [18, 21], and massive endothelial proliferation in pulmonary post-capillary venules [16]. In the renal biopsy undertaken in the last 2 patients we observed TMA with stenotic and occlusive capillaries. Further, there have been reports showing this association [6, 7, 15, 16]. Additionally, the first 2 patients also had renal injury (including proteinuria and microscopic hematuria) and anemia. Furthermore patient 1 had an elevated level of serum LDH and IBIL, and patient 2 had an elevated level of serum LDH, which suggested that both of them might have atypical renal TMA especially patient 1. Renal TMA may be underestimated especially in China because its features are too subtle. None of the 4 patients presented with thrombocytopenia, which was consistent with the report by Komhoff M [6]. There was also imaging evidence of diffuse pulmonary microangiopathic lesions in all 4 of our patients. Therefore, we also speculate that the damage of vascular endothelial cell function (including pulmonary vessels) was triggered by intracellular and systemic changes by MMACHC variants. This was particularly marked in the presence of increased serum homocysteine concentration and could increase the permeability of pulmonary capillaries. The resulting vasoconstriction, vascular smooth muscle cell proliferation, and microthrombus formation, especially pulmonary TMA [1, 7], caused the presence of diffuse ground-glass opacification and centrilobular nodules in the lungs.

In this paper, DLD was diagnosed by lung imaging. DLD is consist of many kinds of lung diseases, including pulmonary vasculopathy.

Our study has several limitations. We did not undertake blood smear examination in the first 3 patients, because of our poor awareness of TMA. Additionally, we did not undertake lung biopsy in the first 3 patients, as it was not warranted by the severity of patients 1 and 2, and the parents of patient 3 declined to give consent. Patient 4 underwent transbronchoscopic lung biopsy, and the histologic findings only showed a thickening of the alveolar septum without vascular structure, owing to the small tissue sample. These patients were not treated with hydroxocobalamin, which was unavailable in mainland China. We used TRPG to estimate PA pressures rather than undertake right heart catheterization, which is substantially more invasive.

Conclusions

CblC defect has biochemical (combined MMA and homocysteinemia), radiological (DLD) and cardiological (PAH) characteristics. Our study suggested combined MMA and homocysteinemia be considered a potential reversible cause of DLD and PAH. Prompt recognition, diagnosis and treatment of CblC defect may reverse not only lung damage, but may prevent other complications associated with CblC defect (renal microangiopathy), and that it should be suspected not only in children, but in adults with similar findings.

Abbreviations

BALF: 

Bronchoalveolar lavage fluid

BMI: 

Body mass index

BUN: 

Blood urea nitrogen

cblC: 

Cobalamin C

DLD: 

Diffuse lung diseases

EF: 

Ejection fraction

Hcy: 

Homocysteine

HRCT: 

High-resolution computed tomography

HUS: 

Hemolytic uremic syndrome

IBIL: 

Indirect bilirubin

LDH: 

Lactate dehydrogenase

MMA: 

Methylmalonic Acidemia

MRI: 

Magnetic resonance imaging

PA: 

Pulmonary arterial

PAH: 

Pulmonary arterial hypertension

PCH: 

Pulmonary capillary hemangiomatosis

PVOD: 

Pulmonary venous occlusive disease

RBCs: 

Red blood cells

TMA: 

Thrombotic microangiopathy

TRPG: 

Tricuspid regurgitation pressure gradient

Declarations

Acknowledgements

We would like to thank Prof. Kaifeng Xu (Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences) and Prof. Chunhua Zhang (Department of Research and Development, MILS International, Kanazawa 921-8105, Japan) for the help in revising the manuscript, the staff at Joy Orient Translational Medicine Research Center for their expert technical assistance. We also thank all of the patients and their families for their kind cooperation.

Funding

This work was supported by Beijing Municipal and Commission Health and Family Planning[2015-3-076]. The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials

Please contact author for data requests.

Authors’ contributions

JL supervised the patient care, conceptualized and designed the report, collected the data, and drafted the initial manuscript; YP supervised the radiological images and revised the article;NZ supervised the patient care and collected the data; XL supervised the patient care; QM supervised the patient care; HX supervised the patient care and collected the data; SZ supervised the patient care, conceptualized the report, and reviewed and revised the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

All patient guardians gave informed consent to the publication of this study.

Ethics approval and consent to participate

The research was approved by the Ethics Committee of Beijing Children’s Hospital. All patient guardians gave informed consent to the study.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Respiratory Medicine, Beijing Children’s Hospital, Capital Medical University
(2)
Imaging Center, Beijing Children’s Hospital, Capital Medical University
(3)
Department of Nephrology, Beijing Children’s Hospital, Capital Medical University

References

  1. Arroliga AC, Sandur S, Jacobsen DW, Tewari S, Mustafa M, Mascha EJ, et al. Association between hyperhomocysteinemia and primary pulmonary hypertension. Respir Med. 2003;97(7):825–9.View ArticlePubMedGoogle Scholar
  2. Wuillemin WA, Solenthaler M. Hyperhomocysteinemia: a risk factor for arterial and venous thrombosis. Vasa. 1999;28(3):151–5.View ArticlePubMedGoogle Scholar
  3. Profitlich L, Kirmse B, Wasserstein MP, Diaz G, Srivastava S. Resolution of cor pulmonale after medical management in a patient with cblC-type methylmalonic aciduria and homocystinuria: a case report. Cases J. 2009;2:8603.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Gunduz M, Ekici F, Ozaydin E, Ceylaner S, Perez B. Reversible pulmonary arterial hypertension in cobalamin-dependent cobalamin C disease due to a novel mutation in the MMACHC gene. Eur J Pediatr. 2014;173(12):1707–10.View ArticlePubMedGoogle Scholar
  5. Iodice FG, Di Chiara L, Boenzi S, Aiello C, Monti L, Cogo P, et al. Cobalamin C defect presenting with isolated pulmonary hypertension. Pediatrics. 2013;132(1):e248–51.View ArticlePubMedGoogle Scholar
  6. Komhoff M, Roofthooft MT, Westra D, Teertstra TK, Losito A, van de Kar NC, et al. Combined pulmonary hypertension and renal thrombotic microangiopathy in cobalamin C deficiency. Pediatrics. 2013;132(2):e540–44.View ArticlePubMedGoogle Scholar
  7. Grangé S, Bekri S, Artaud-Macari E, Francois A, Girault C, Poitou AL, et al. Adult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency. Lancet. 2015;386(9997):1011–2.View ArticlePubMedGoogle Scholar
  8. George JN. Cobalamin C, deficiency-associated thrombotic microangiopathy: uncommon or unrecognised? Lancet. 2015;386(9997):1012.View ArticlePubMedGoogle Scholar
  9. Qi YH, Qi JG, Liu YP, Yan H, Liu XQ, Zhang X, et al. Clinical analysis and follow-up study of cardiavascular system involvement in 10 children withmethylmalonic aciduria combined with hyperhomocysteinemia. Zhongguo Dang Dai Er Ke Za Zhi. 2015;17(9):965–70.PubMedGoogle Scholar
  10. Lerner-Ellis JP, Tirone JC, Pawelek PD, Doré C, Atkinson JL, Watkins D, et al. Identification of the gene responsible for methylmalonic aciduria and homocystinuria, cblC type. Nat Genet. 2006;38(1):93–100.View ArticlePubMedGoogle Scholar
  11. Huemer M, Scholl-Bürgi S, Hadaya K, Kern I, Beer R, Seppi K, et al. Three new cases of late onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy. Orphanet J Rare Dis. 2014;9:161.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Wang F, Han L, Yang Y, Gu X, Ye J, Qiu W, et al. Clinical, biochemical, and molecular analysis of combined methylmalonic acidemia and hyperhomocysteinemia (cblC type) in China. J Inherit Metab Dis. 2010;33 Suppl 3:S435–42.View ArticlePubMedGoogle Scholar
  13. Liu MY, Yang YL, Chang YC, Chiang SH, Lin SP, Han LS, et al. Mutation spectrum of MMACHC in Chinese patients with combined methylmalonic aciduria and homocystinuria. J Hum Genet. 2010;55(9):621–6.View ArticlePubMedGoogle Scholar
  14. Li QL, Song WQ, Peng XX, Liu XR, He LJ, Fu LB. Clinical characteristics of hemolytic uremic syndrome secondary to cobalamin C disorder in Chinesechildren. World J Pediatr. 2015;11(3):276–80.View ArticlePubMedGoogle Scholar
  15. Beck BB, van Spronsen F, Diepstra A, Berger RM, Kömhoff M. Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity. Pediatr Nephrol. 2016 Jun 11. [Epub ahead of print]Google Scholar
  16. Bouts AH, Roofthooft MT, Salomons GS, Davin JC. CD46-associated atypical hemolytic uremic syndrome with uncommon course caused by cblC deficiency. Pediatr Nephrol. 2010;25(12):2547–8.View ArticlePubMedPubMed CentralGoogle Scholar
  17. De Bie I, Nizard SD, Mitchell GA. Fetal dilated cardiomyopathy: an unsuspected presentation of methylmalonic aciduria and hyperhomocystinuria, cblC type. Prenat Diagn. 2009;29(3):266–70.View ArticlePubMedGoogle Scholar
  18. Brandstetter Y, Weinhouse E, Splaingard ML, Tang TT. Cor pulmonale as a complication of methylmalonic acidemia and homocystinuria (Cbl-C type). Am J Med Genet. 1990;36(2):167–71.View ArticlePubMedGoogle Scholar
  19. Agarwal R, Feldman GL, Poulik J, Stockton DW, Sood BG. Methylmalonic acidemia presenting as persistent pulmonary hypertension of the newborn. J Neonatal Perinatal Med. 2014;7(3):247–51.PubMedGoogle Scholar
  20. Baumgartner ER, Wick H, Maurer R, Egli N, Steinmann B. Congenital defect in intracellular cobalamin metabolism resulting in homocysteinuria and methylmalonic aciduria. I. Case report and histopathology. Helv Paediatr Acta. 1979;34(5):465–82.PubMedGoogle Scholar
  21. Russo P, Doyon J, Sonsino E, Ogier H, Saudubray JM. A congenital anomaly of vitamin B12 metabolism: a study of three cases. Hum Pathol. 1992;23(5):504–12.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement